ARTICLE | Clinical News
Baricitinib regulatory update
January 25, 2016 8:00 AM UTC
Eli Lilly submitted an NDA to FDA for once-daily oral baricitinib to treat moderately to severely active rheumatoid arthritis. The submission triggered a $35 million milestone payment to Incyte from L...